"The US Food and Drug Administration has approved a pill version of the drug Wegovy from Novo Nordisk as a treatment for weight loss. The pill was approved for chronic weight management in adults with obesity or overweight and at least one related health condition. The oral medication contains semaglutide, the same active ingredient in Wegovy and Ozempic, which is also made by Novo Nordisk and primarily prescribed for type 2 diabetes."
"Novo said the 1.5-milligram starting dose of the Wegovy pill will be available in early January and will cost $149 (126) per month from some providers. Additional information on cost will be available in January. A daily pill gives doctors another option for prescribing GLP-1 medicines for obesity and could broaden patient access and reduce costs. Wegovy as well as Eli Lilly's weight-loss drug Zepbound are normally injected once a week."
The FDA approved an oral form of Wegovy (semaglutide) for chronic weight management in adults with obesity or overweight who have at least one related health condition. The oral medication uses the same active ingredient as injectable Wegovy and Ozempic and follows an earlier oral semaglutide for diabetes, Rybelsus. Novo Nordisk plans to make a 1.5‑milligram starting pill available in early January, with some providers listing a monthly price of $149. A daily pill provides an alternative to weekly injections, potentially broadening access and lowering costs. About 40% of U.S. adults and 21% of children and teens are obese; roughly 12% report current GLP-1 use.
Read at www.dw.com
Unable to calculate read time
Collection
[
|
...
]